Pharmiweb ChannelsAll | PharmaCo | Clinical Research | R&D/BioTech | Sales/Mktg | Healthcare | Recruitment | Pharmacy | Medical Comms RSS Feed RSS Feeds


Press Release

FIT Biotech Oy: FIT Biotech Oy's Board of Directors has decided on the directed share issue without payment to the Company itself

FIT Biotech Oy
Posted on: 21 Feb 18

FIT Biotech Oy
Company release February 21, 2018 at 3.30 pm EET

FIT Biotech Oy's Board of Directors has decided on the directed share issue without payment to the Company itself

FIT Biotech Oy's Board of Directors has resolved to issue 150,000,000 new K shares without payment to the Company itself based on the authorization granted by the extraordinary general meeting on December 14, 2017 (Extraordinary general meeting Point 9§).

The total authorization was 550,000,000 K shares. The Board of Directors has decided earlier to issue 180,000,000 new K shares. There are authorizations for 220,000,000 K shares left after this issuance.

The purpose is partly to use the shares to implement the new Alpha Blue Ocean funding programme, disclosed on December 23, 2017 and partly to implement the remaining part of the Bracknor funding programme.

Board of Directors

For further information:
CEO Erkki Pekkarinen
Tel: +358 44 027 0080

Certified Advisor: Aalto Capital Partners Oy, tel. +358 40 587 7000

About FIT Biotech

FIT Biotech Oy is a biotechnology company established in 1995. The company develops and licenses its patented GTU® (Gene Transport Unit) vector technology for new-generation medical treatments. GTU® is a gene transport technology that meets an important medical challenge in the usability of gene therapy and DNA vaccines.

FIT Biotech applies GTU® technology in its drug development programmes. Application areas include cancer (gene therapy) and infectious diseases such as HIV and tuberculosis, as well as animal vaccines.

FIT Biotech shares are listed on the First North Finland marketplace maintained by Nasdaq Helsinki Oy.

Principal media

This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.

The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: FIT Biotech Oy via GlobeNewswire

Last updated on: 22/02/2018

Site Map | Privacy & Security | Cookies | Terms and Conditions is Europe's leading industry-sponsored portal for the Pharmaceutical sector, providing the latest jobs, news, features and events listings.
The information provided on is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her physician.